1Cubeddu LX. QT prolongation and fatal arrhythmias: A review of clinical implications and effects of drugs. Am J Ther, 2003,10:452-457.
2Owczuk R, Wujtewicz MA, Sawicka W, et al. Is prolongation of the QTc interval during isoflurane anaesthesia more prominent in women pretreated with anthracyclines for breast cancer? Br J Anaesth,2004,92:658-661.
3Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin - containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol, 2001,19 : 2746-2753.
4Zehser D, Justo D, Halkin A, et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine, 2003,82: 282-290.
5Yang P, Kanki H, Drolet B, et al. Allelic variants in Long-QT disease genes in patients with drug-associated torsades de pointes. Circulation, 2002,105 : 1943-1948.
7Choy AM, Lang CC, Chomsky DM, et al. Nomlalization of acquired QT prolongation in humans by intravenous potassium. Circulation, 1997, 96: 2149-2154.
8Moss AJ, Zareba W, Benhorin J, et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation, 1995,92: 2929-2934.
9Viskin S. Long QT syndromes and torsade de pointes, Lancet, 1999,354: 1625-1633.
10Booker PD, Whyte SD, Ladusans EJ. Long QT syndrome and anaesthesia. Br J Anaesth, 2003,90: 349-366.
